Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation

DOI:
10.1002/path.5074

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):
May, S., Owen, H., Phesse, T. J., Greenow, K. R., Jones, G-R., Blackwood, A., Cook, P. C., Towers, C., Gallimore, A. M., Williams, G. T., Stürzl, M., Britzen-Laurent, N., Sansom, O. J., MacDonald, A. S., Bird, A. P., Clarke, A. R., & Parry, L. (2018). Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. *The Journal of pathology, 245*(3), 270-282. Advance online publication. https://doi.org/10.1002/path.5074

Published in:
The Journal of pathology

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Download date:08. Oct. 2023
Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation

Stephanie May¹, Heather Owen², Toby J Phesse¹, Kirsty R Greenow¹, Gareth-Rhys Jones³, Adam Blackwood¹, Peter C Cook³, Christopher Towers¹, Awen M Gallimore⁴, Geraint T Williams⁵, Michael Stürzl⁶, Nathalie Britzen-Laurent⁶, Owen J Sansom⁷, Andrew S MacDonald³, Adrian P Bird², Alan R Clarke¹, Lee Parry¹

¹European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff, Wales, UK
²Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann Building, Edinburgh, Scotland, UK
³Manchester Collaborative Centre for Inflammation Research, Manchester, UK
⁴Cardiff Institute of Infection & Immunity, Henry Wellcome Building, Cardiff, Wales, UK
⁵Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, Wales, UK
⁶University Hospital Erlangen, Department of Molecular and Experimental Surgery, Erlangen, Germany
⁷Cancer Research UK Beatson Institute, Glasgow, UK

Correspondence to: Lee Parry, European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Maindy Road, Cardiff, CF24 4HQ. Phone: +44-29-20688017; Email: parryl3@cardiff.ac.uk

Conflict of interest: None to declare.

Running title: Opposing roles for Mbd2 in inflammation and tumourigenesis

ABSTRACT

Epigenetic regulation plays a key role in the link between inflammation and cancer.

Here we examine Mbd2, which mediates epigenetic transcriptional silencing by
binding to methylated DNA. In separate studies the Mbd2−/− mouse has been shown to be (1) resistant to intestinal tumourigenesis and (2) have an enhanced inflammatory/immune response; observations that are inconsistent with the links between inflammation and cancer. To clarify its role in tumourigenesis and inflammation, we used constitutive and conditional models of Mbd2 deletion to explore its epithelial and non-epithelial roles in the intestine. Using a conditional model, we found that suppression of intestinal tumourigenesis is due primarily to the absence of Mbd2 within the epithelia. Next, we demonstrated, using the DSS colitis model, that non-epithelial roles of Mbd2 are key in preventing the transition from acute to tumour-promoting chronic inflammation. Combining models revealed that prior to inflammation the altered Mbd2−/− immune response plays a role in intestinal tumour suppression. However, following inflammation the intestine converts from tumour suppressive to tumour promoting. To summarise, in the intestine the normal function of Mbd2 is exploited by cancer cells to enable tumourigenesis, while in the immune system it plays a key role in preventing tumour-enabling inflammation. Which role is dominant depends on the inflammation status of the intestine. As environmental interactions within the intestine can alter DNA methylation patterns, we propose that Mbd2 plays a key role in determining whether these interactions are anti- or pro-tumourigenic and this makes it a useful new epigenetic model for inflammation-associated carcinogenesis.

**Keywords:** Colon cancer, DSS colitis, Inflammation, Epigenetics.

**INTRODUCTION**

Epigenetic regulation of the genome plays a major role in human health and disease [1]. DNA methylation, via addition of a methyl group to the fifth carbon of cytosine in
a CpG dinucleotide [2], is a fundamental epigenetic modification. As DNA methylation can be influenced by the environment it plays a large role in the biology of diseases with a strong environmental component, such as the intestine [3,4]. DNA methylation is synonymous with transcriptional silencing as it can either inhibit binding of transcription regulators, such as c-Myc [5], or recruit co-repressor complexes that trigger the formation of repressive chromatin [6]. These co-repressor complexes are recruited by proteins which bind directly to methylated DNA to mediate a cell’s complex multi-layered transcriptional program. These methyl-binding proteins act as “master controllers” by mediating the effects of DNA methylation, thus they can regulate many genes simultaneously, including aberrantly methylated genes that lead to disease [4]. One of these proteins, methyl binding domain protein 2 (Mbd2) has been shown to play crucial roles in various biological processes and disease [4,7]. The importance of its role has been highlighted using mouse models where its deficiency has been shown to influence intestinal inflammatory responses [8-13] and epithelial cell biology [14-16]. These multiple roles potentially make it a unifying player in the myriad of biological processes that contribute to the initiation and development of intestinal cancer.

Using the Apc+/min model[17] we have previously demonstrated that the Mbd2-/- mouse is resistant to Wnt-driven tumourigenesis [15,16] - the most common type of human colorectal cancer (CRC). Further, we demonstrated that Mbd2 deficiency in a Wnt activated intestine reduces the expression of Wnt target genes, including C-myc [15]. Potentially, this attenuation of tumourigenesis is due to a lack of Mbd2 dependent silencing of tumour suppressor genes, however, the mechanism of Apc+/min Mbd2-/- tumour suppression remains unknown. During the course of these studies we reported that Mbd2 deficiency in Wnt activated intestinal epithelia relieved
silencing of genes associated with immune responses [15]. This is in accordance with previously reported roles for Mbd2 in guiding cells down the different epigenetically regulated T cell lineages [8-13]. This presents within the intestine of the Mbd2−/− mouse as an excessive type 1 response upon immune challenge[18], characterised by an increase in the expression of the pro-inflammatory cytokine interferon gamma (Ifng). Evidence from mice and humans suggests an anti-tumourigenic role for Ifng in colorectal cancer (CRC), as a loss of Type 1 cytokines accompanies the adenoma-carcinoma sequence in the colorectum [19], intestinal tumourigenesis is promoted in mice deficient for Ifng or its receptors[20] and Th1 cytokines lead to cancer senescence [21]. This role is due, at least in part, to Ifng mediated C-myc inhibition [22,23] and increased expression of the HLA-DR antigen [22]; features we previously reported in the Wnt activated Mbd2 deficient intestine [22]. However, in its inflammatory role Ifng is causally involved in inflammatory bowel diseases, where chronic inflammation drives cellular and molecular inflammatory mechanisms that underlie tumour initiation[24,25]. Evidence from other tissues indicates the tussle between the anti- and pro-tumourigenic functions of Ifng seems to be dependent on the contexts of tumour specificity, micro-environmental factors and signalling intensity[26].

Here we examine how the increased inflammatory response and tumour suppression phenotype interact in the Mbd2 deficient mouse intestine. Our findings highlight separate roles for Mbd2 in controlling intestinal inflammation and enabling epithelial tumourigenesis.

**MATERIALS AND METHODS**

**Animal Models**
All animal procedures were conducted in accordance with institutional animal care guidelines and UK Home Office regulations. In brief, mice were maintained in a specific pathogen free (SPF) barrier facility in conventional open top cages on Eco-Pure Chips 6 Premium bedding (Datesand, Manchester, UK), under a 12h light cycle with IPS 5008 diet (Labdiet-IPS Ltd, London, UK) provided for nutritional support. To enrich the environment irradiated sunflower seeds (at weaning only), Techniplast mouse houses (Techniplast, Leicester, UK) and small chewsticks (Labdiet-IPS Ltd) were provided. All mice were from a mixed background and were homozygous with respect to the C57Bl/6 Pla2g2a (also called Mom-1) allele. Experimental animals were between 10–15 weeks old with siblings used as controls. The alleles for the \( Ah-cre^{+\text{min}, \text{Ifng}^{-}} \) [27], \( Apc^{+/\text{min}} \), \( Lgr5creER^{T2} \) [29], \( Mbd2^{-/-} \) [9], \( Mbd2^{\text{flx/flx}} \) [13] and \( vil-creER^{T2} \) [30] have been described previously. Induction of the \( Ah-cre \) transgene was performed by administering three intra-peritoneal (I.P.) injections of \( \beta \)-naphthoflavone (BNF; Sigma, Gillingham, Dorset, UK) at 80 mg/kg in a 24 h period. Induction of the \( Lgr5creER^{T2} \) and \( vil-creER^{T2} \) transgenes was achieved by administering a single injection of tamoxifen (TAM 80 mg/kg I.P.; Sigma,) for four consecutive days. For induction of colitis (acute inflammatory insult) mice were given dextran sodium sulphate (m.w. 36000-50000; MP Biomedicals, Fisher Scientific, Loughborough, UK) \textit{ad libitum} in drinking water at the concentration (w/v) and duration stated. Colitis disease severity was measured according to published protocols [31]. For survival analysis mice were harvested at either a specific time point or a humane endpoint when mice displayed phenotypes indicative of acute colitis (weight loss and diarrhoea) or tumour burden (pale feet, bloating, prolapse or piloerection). Tumour burden was measured at point of death by removing the entire intestine and mounting \textit{en face} in methacarn fixative (4:2:1 methanol, chloroform,
and glacial acetic acid), to determine the number of macroscopic lesions and their size.

**Revers Transcription – quantitative PCR (RT-qPCR) analyses**

The following methods were performed according to manufacturer’s instructions unless otherwise stated. For analysis of gene expression in the intestine three to five mice from each control and experimental group were harvested. RNA was extracted either from a 0.5 cm portion of whole large intestine taken ~1 cm distally from the caecum or from crypt epithelia extracted from the whole large intestine, samples were stored at -80 °C in RNAlater (Sigma, UK) [32]. Total RNA was extracted using the RNeasy kit (Qiagen, UK) and DNase treated using the Turbo DNase kit (Fisher Scientific). Complimentary DNA (cDNA) was reverse transcribed from 1 µg of RNA using random hexamers (Promega, Southampton, UK) and the Superscript III (Fisher Scientific) kits. For relative quantitation all samples were run in duplicate on the StepOnePlus PCR machine using Fast Sybr Green master mix (Applied Biosystems, UK) or Taqman Universal Mastermix II (Fisher Scientific). The threshold cycle (Ct) values of each gene analysed were normalised to a reference gene. For expression analysis Ct values were normalised against the Actb gene (mouse) or RPL37A (human). Oligonucleotide sequences used for relative quantification are available upon request. Differences between groups were assessed using the $2^{-\Delta\Delta Ct}$ method[33]. Two-tailed Mann-Whitney U (M.W.) tests were performed on the $\Delta Ct$ values and differences with P values <0.05 were considered significant [34].
Reporter visualization, immunohistochemistry (IHC) and cellular analysis

For IHC, tissue was fixed in ice cold 10% neutral sodium phosphate buffered formalin (Sigma) and processed into wax blocks by conventional means. Section were cut at 5 µm thickness, dewaxed, and rehydrated into PBS. Staining was performed using the Envision+ mouse or rabbit kit (Dako, Agilent Ltd, Stockport, UK) according to manufacturer's instructions. To identify cells which had lost Apc we used nuclear β-catenin as a surrogate marker, using a mouse monoclonal anti-β-catenin antibody (Cat No#610154, BD Biosciences, Wokingham, UK) at 1:200. For Paneth cell detection, we used a rabbit polyclonal anti-lysozyme antibody (Cat No# RB-372, Neomarkers/Labvision, Fisher Scientific) at 1:200. CD4 cells were stained with a mouse anti CD4 antibody (Clone 4sm95, eBioscience, Fisher Scientific; 1/50). To visualize mucin and goblet cells slides were stained with Alcian Blue. The cells between the base of the crypt and the junction with the villus was designated as the proliferative zone. Cellular analysis was performed on >25 whole crypts from at least three mice of each genotype. Slides were scanned for analysis using the Axioscan Z1 slide scanner (Zeiss, Cambridge, UK) and images excised from scans using the Zeiss Axioscan Zen software.

T cell analysis

To label the Th1 and Th2 cytokines in serum we used a Cytometric Bead Array Mouse Th1/Th2/Th17 Cytokine kit (BD Biosciences) following the manufacturer’s instructions and using a FACS Canto II BD Biosciences). To characterize the immune cell populations, single cell suspensions of lymphocytes were prepared from large intestine lamina propria [35,36]. Lymphocytes were stimulated for 4 h using ionomycin, phorbol myristate acetate (Sigma) and 1 µg/ml Golgistop (Sigma). Prior
to flow cytometry, lymphocytes were stained with fluorescent conjugated antibodies against CD4 (RM-4-5, 1/800), Ifng (XMG1.2, 1/200), Il-13 (eBIO 13a, 1/200), TCRa/b (MR5.2, 1/200) (all Fisher Scientific), CD45 (30-F11, 1/200), CD8 (53-6.7, 1/200), Il-4 (11B11, 1/200) (all Biolegend, London, UK), Il-17 (TC11-18H10.1, 1/100) and TNF (MP6-XT22, 1/200) (both BD Biosciences) and a live/dead marker. Data was analysed using FCAP Array v3.0 (BD Biosciences) and FlowJo (FlowJo LLC, Ashland, OR, USA) software. Statistical analysis was performed using 3-5 animals per genotype and 3 independent experiments. Significance was calculated using a 3-way full factorial fit model and a joint F-test to assess effects of genotype, treatment and experiment day on the cytokine response [37]

Statistical analysis

All preclinical data were evaluated with GraphPad Prism software, version 7.02 (GraphPad, La Jolla, CA, USA). When 2 variables were compared, 2-tailed Mann-Whitney test was performed. Survival data was analysed using the Kaplan-Meier test. The relationship between genotype and phenotype was assessed using Fisher’s Exact test. If not indicated otherwise, the statistical mean is presented, and error bars represent S.E.M. On graphs, P-values are indicated as follows: *P < 0.05; **P < 0.01; ***P <0 .001.

Grant support:

This work was supported by a programme grant from Cancer Research UK. Lee Parry is supported by a fellowship from the European Cancer Stem Cell Research Institute.

RESULTS
Intestinal epithelial loss of Mbd2 is sufficient to suppress tumourigenesis

Potentially, the intestinal tumour resistance of the Mbd2\(^{−/−}\) mouse is due to an enhanced anti-tumourigenic Th1/Ifng response, a loss of Mbd2 epigenetic regulation within the intestinal epithelia or a combination of both. To clarify this situation, we utilised a conditional Cre-Lox mouse to delete Mbd2 solely within the intestinal epithelia, allowing us to establish the epithelial contribution of Mbd2 to tumourigenesis. Mice carrying the Ah-cre and Mbd2\(^{ex1/ex1}\) transgenes were crossed to generate Ah-creMbd2\(^{ex1/ex1}\) mice, which following BNF induction deleted exon 1 of Mbd2 specifically within the crypts of the intestinal epithelia. Cohorts of 4-6 mice were examined four days after deletion. In comparison to control cohorts, there was no alteration to the expression of Wnt target genes (C-myc and Axin2), size of the crypt proliferative zone, Paneth cell localisation (Figure 1A-C) or genes characteristic of the differentiated cell types (supplementary material, Figure S1). To investigate the epithelial role of Mbd2 on Wnt signalling, Ah-creMbd2\(^{ex1/ex1}\) mice were crossed to mice carrying an Apc\(^{flx}\) allele, to generate Ah-creApc\(^{flx/flx}\) Mbd2\(^{ex1/ex1}\) and control cohorts. Upon Ah-cre driven Apc loss we observed an upregulation of Wnt target genes, increase in the size of the crypt proliferative zone and mislocalisation of Paneth cells (Figure 1A-C), as we have previously reported [38]. In comparison, the increase in expression of Wnt target genes Axin2 (P=0.0159) and C-myc (P=0.0159), due to Apc deletion, was significantly attenuated by additional loss of Mbd2 (P=0.0159) (Figure 1A). This corresponded with a decrease in the size of the proliferative zone within the crypts of Leiberkühn (Figure 1B) and a partial rescue of the mislocalisation of Paneth cells (a characteristic of Ah-cre driven Apc loss) (Figure 1C). These findings are consistent with our previously reported data using the Ah-creApc\(^{flx/flx}\) Mbd2\(^{−/−}\) model[15], in which Mbd2 is absent systemically. To investigate
whether these changes would influence the initiation of intestinal tumourigenesis, cohorts of Ah-creApc+/flx (N=20) and Ah-creApc+/flxMbd2 ex1/ex1 (N=23) mice were induced at 10–12 weeks of age and harvested at 180 days post induction (dpi). These mice are equivalent to the Apc+/min model, as they require the spontaneous loss of the remaining wild type allele for tumour initiation. The Ah-creApc+/flxMbd2 ex1/ex1 cohort showed a significant increase in survival compared to Ah-creApc+/fl control cohort (Figure 2A). Expression analysis on whole intestine from 6-8 animals within each cohort confirmed the continued absence of Mbd2 within the epithelia (Figure 2B). At a 180 dpi Ah-creApc+/flxMbd2 ex1/ex1 had significantly fewer tumours and reduced burden compared to the control cohort (Figure 2C). In summary, the absence of Mbd2 within the intestinal epithelia is well tolerated and sufficient to suppress Wnt signalling and tumourigenesis, replicating the phenotype observed in the Apc+/minMbd2-/- mice and demonstrating a cell intrinsic mechanism for Mbd2. We next sought to investigate the role that Mbd2 plays in intestinal inflammation.

**Mbd2 deficiency exacerbates DSS-induced colitis**

As previous reports demonstrated that the Mbd2-/- mice have an enhanced CD4+ T helper type 1 response, characterised by an increase in Ifng levels, we first sought to verify this in our mice[8,9]. Lymphocytes were isolated from the large intestine lamina propria of WT and Mbd2-/- mice and characterised using flow cytometry. The Mbd2-/- mice displayed a significant increase in the numbers of CD4+Ifng+ (Figure 3A) and CD8+cells expressing IL-4, IL-17, Ifng, and TNF, with CD8+ cells also displaying increased expression of IL-13 (Figure 3A,B), similar to previously published data[18]. The significantly elevated Ifng levels were further confirmed by an increase in mRNA expression and Ifng presence in the serum. (supplementary
material, Figure S2A,B). To investigate the impact of these changes on the large intestine, cohorts of ≥6 mice were administered 2% DSS (w/v) in drinking water ad libitum for 6 days to induce acute inflammation, experiments were repeated three times to assess reproducibility. The $Mbd2^{-/-}$ mouse demonstrated a significant increase in the disease activity index (DAI), histology score, weight loss and large intestine atrophy compared to control mice (Figure 3C; supplementary material, Figure S2C-E). Analysis of lymphocytes from the lamina propria indicated an altered cytokine profile with a significant increase in CD4+ cells positive for IL-17, Ifng, TNF and CD8+Ifng+ cells (Figure 3B and D). As a key role for CD4+ cells and Ifng in DSS induced colitis has been previously shown we repeated this experiment using Ifng$^{-/-}$ mice and neutralising CD4+ antibodies to determine their contribution to the phenotype. The absence of Ifng suppressed colitis, as previously shown [39] and significantly decreased severity in the $Mbd2^{-/-}$Ifng$^{-/-}$ double knockout (Figure 3C). To address the importance of the CD4+ lymphocyte population, $Mbd2^{-/-}$ and control mice were administered a CD4 neutralising antibody -3, -1 and 0 days prior to induction of acute inflammation. The blockade of CD4+ cells reduced the DAI and weight loss scores to the levels previously observed by deleting Ifng (Figure 3C). To investigate whether the epithelial loss of Mbd2 played a role in the altered immune response we generated cohorts of vil-creERT2$Mbd2^{ex1/ex1}$, to drive Mbd2 deletion in the large intestinal epithelia. Four days after deletion of Mbd2, mice were exposed to 2% DSS in drinking water ad libitum. Six days following DSS exposure the vil-CreERT2$Mbd2^{ex1/ex1}$, in comparison to control mice, displayed a significant 4-fold decrease in Mbd2 expression within the large intestine crypt epithelia, but no difference in overall disease severity (supplementary material, Figure S3A,B). Further expression analysis within the large intestine indicated no alteration to genes characteristic of
Th1 (Ifng), Th17 (Tbx21) and Tregs (Foxp3), which we previously demonstrated to be altered in the Mbd2\(^{-/-}\) setting [8,10,12] (supplementary material, Figure S3C). In summary, the Mbd2\(^{-/-}\) mouse is highly susceptible to DSS induced colitis, at least in part, due to the loss of Mbd2 function specifically within the CD4+ cells and loss of appropriate regulation of the pro-inflammatory cytokine Ifng. However, additional roles for Mbd2 within the non-epithelial cells of the stromal compartment cannot be discounted due to the epithelial specific nature of the villinCreERT\(^{T2}\) model. We next sought to establish the role of this inflammation susceptibility in a cancer setting.

**DSS exposure leads to chronic mucosal colitis and tumourigenesis in the Mbd2\(^{-/-}\) mouse**

To determine whether this increased susceptibility to colitis had a long-term effect on intestinal health, cohorts of control and Mbd2\(^{-/-}\) mice were administered 2% DSS for 6 days *ad libitum* and aged for 30, 60 and 170 days. The control Mbd2\(^{+/+}\) littermates made a complete recovery following withdrawal of DSS and at 30 (N=9) and 170 days (N=11) post inflammation showed no sign of intestinal disease (Figure 4A). In contrast the Mbd2\(^{-/-}\) mice failed to resolve the inflammation and developed a chronic mucosal colitis. At 30 days 83% (5/6, P=0.002) of Mbd2\(^{-/-}\) mice showed continuing signs of colitis which include severe mucosal inflammation with severe diarrhoea, widespread crypt loss, superficial ulceration, focal active cryptitis with scattered crypt abscesses and patches of epithelial regeneration (Figure 4B and supplementary material, Figure S4A). At 60 days the severe diarrhoea and bleeding had subsided in all mice (n=6), however, in the intestines of 66% (4/6) of these mice an active chronic mucosal colitis remained, with a mononuclear cell infiltrate in the lamina propria, distortion of crypt architecture, regenerative epithelial hyperplasia.
and crypt fission (supplementary material, Figure S4B). At 170 dpi 60% (6/10, P=0.0039) of the mice had flat lesions which were classified as mucinous adenocarcinoma (Figure 4C and supplementary material, Figure S4C). These lesions displayed nuclear β-catenin staining indicating they were driven via deregulation of the Wnt pathway (Figure 4D and supplementary material, Figure S4C). We have previously shown that absence of Mbd2 in the epithelial alone is not sufficient to alter the acute immune response (supplementary material, Figure S3B), to confirm there was not a longer-term phenotype we generated cohorts of vil-
creER\textsuperscript{T2}Mbd2\textsuperscript{ex1/ex1} for analysis. At 180 days following exposure to 2% DSS in drinking water given ad libitum these mice, in contrast to the the systemic Mbd2\textsuperscript{−/−} setting, showed no signs of intestinal disease (data not shown). This data suggests the switch to a tumour promoting environment is dependent on loss of Mbd2 in cells outside of the intestinal epithelia, with the cells of the immune system being the most likely candidates. We next sought to establish the effect of the Mbd2\textsuperscript{−/−} inflammatory response on the tumour suppression observed in the Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} intestine.

**Chronic inflammation overcomes Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} intestinal tumour suppression**

As the Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} is resistant to intestinal tumourigenesis we addressed whether this is still the case following an acute inflammatory insult. Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} mice at 10–12 weeks old were exposed to 2% DSS (w/v) for 6 days and allowed to age for 30 and 180 days. At 30 days after DSS withdrawal all Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} mice (4/4) still presented with chronic colitis (Figure 5A). At 180 days post DSS 72% (8/11) of Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} mice displayed mucinous adenocarcinoma with nuclear β-catenin (Figure 5B, in contrast to control Apc\textsuperscript{+/−}Mbd2\textsuperscript{−/−} mice which remained disease free at
the same age, as reported previously [16]. These lesions presented as flat tumours in contrast to the standard polypoid type lesions with extensive nuclear β-catenin that developed in the Apc<sup>+/min</sup> model (Figure 5C). Thus, following the onset of a chronic inflammatory response tumour suppression is lost in the Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> large intestine; indicating that the protection afforded by the absence of Mbd2 in the epithelia is overcome following the onset of an Mbd2 deficient inflammatory response in the intestine.

**Loss of Mbd2 decreases survival of Apc deficient stem cells**

Comparing the data from our Ah-cre Apc<sup>+/flx</sup>Mbd2<sup>ex1/ex1</sup> and our previously published Ah-cre Apc<sup>+/flx</sup>Mbd2<sup>−/−</sup> [15] and Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> [16] mice indicated that the suppression of tumorigenesis, Wnt activation and Paneth cell relocation phenotypes were enhanced in the Mbd2<sup>−/−</sup> mouse. This data suggested that in the Mbd2<sup>−/−</sup> model the epithelial and non-epithelial phenotypes synergised to suppress tumourigenesis. As we have demonstrated a significant role for Ifng in the Mbd2<sup>−/−</sup> inflammatory response and it is a key player in inflammation and anti-tumour immune responses [19,21,22,24,40,41] we sought to assess the relevance of Ifng in the tumour suppression observed in Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> mice. We generated Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> Ifng<sup>−/−</sup> mice to explore whether loss of Ifng impacted on intestinal tumour suppression. As expected at 60 days the Apc<sup>+/min</sup> (N=6) mice displayed significantly more nuclear β-catenin positive lesions (average 22) in comparison to the Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> mice (N=6; average <1) (Figure 6A). As we have previously demonstrated that epithelial loss of Mbd2 alone is capable of intestinal tumour suppression (Figure 1) it is of note that the Apc<sup>+/min</sup> Mbd2<sup>−/−</sup> Ifng<sup>−/−</sup> mice (N=6) displayed a small but significant increase in nuclear β-catenin positive lesions (P=0.03;
average 2.6). Indicating that in the absence of *Ifng* a small number of lesions can escape the tumour resistance conferred by epithelial *Mbd2* loss. In our previous work, where we investigated mice 4 d after acute *Apc* loss in the crypts of Mbd2−/− mice, this information may have been obscured [15]. As this acute *Apc* loss does not reflect the small number of mutated cells which initiate an individual tumour *in vivo* and presents over an insufficient time for an adaptive immunological anti-tumorigenic phenotype to manifest. To overcome this, we targeted gene deletion to the intestinal stem cell (ISC) using the Lgr5cre transgene to generate 

\[ \text{Lgr5creER}^{T2}\text{Apc}^{\text{flx/flux}}\text{Mbd2}^{\text{flx/flux}} \]  and \[ \text{Lgr5CreERT2Apc}^{+}\text{flx/fluxMbd2}^{-/-} \]  mice. These allowed us to delete *Apc* specifically within a proportion of ISCs, the cell of origin for CRC [42], allowing us to observe the effects of *Mbd2* deficiency on *Apc* deleted ISCs over a longer (15-day) time frame. In comparison to the control \[ \text{Lgr5CreERT2Apc}^{\text{flx/flux}} \]  (N=6) mice we observed a significant reduction in the number of nuclear β-catenin lesions in the \[ \text{Lgr5CreERT2Apc}^{\text{flx/flux}}\text{Mbd2}^{-/1/-1} \]  (N=7) cohort, which was further reduced in the \[ \text{Lgr5CreERT2Apc}^{-}\text{flx/fluxMbd2}^{-/-} \]  (N=6) cohort (Figure 6B-D; supplementary material, Figure S5A-C). Potentially the increased reduction of lesions in the *Mbd2−/−* is due to synergy between the enhanced anti-tumourigenic Th1/*Ifng* response and the loss of *Mbd2* mediated transcriptional silencing in the ISC. However, a role for other cells within the *Mbd2−/−* mouse cannot be excluded with this system.

**MBD2 loss is a rare event in colorectal cancer**

Our data presented here and previously [15,16] support that in murine intestinal epithelium *Mbd2* is required to permit intestinal tumourgenesis. To investigate the relevance of *MBD2* in human intestinal cancer we looked for evidence that it is preferentially retained in colorectal cancer, and whether its loss is associated with a
positive prognosis. To achieve this, we examined *MBD2* expression in a panel of human intestinal tumours (TNM stage I-IV, N=7 per stage), expression analysis failed to detect any loss or alteration to the *MBD2* profile across the different tumour stages (supplementary material, Figure S6). We also examined publicly available colorectal cancer sequencing data using cBioPortal (www.cbiportal.org). *In silico* analysis indicated that the *MBD2* gene was classed as deep deleted in 6/2079 (0.28%) patients; while supportive of a role for *MBD2* in enabling tumourigenesis, the small number of samples in which *MBD2* was lost prevented any conclusive survival analysis.

**DISCUSSION**
Based on this preclinical data, the genes transcriptionally regulated by Mbd2 within the immune system and stem cells from the normal and diseased intestinal epithelia offer a set of targets that play a key role in linking epigenetic changes to cancer. The finding that within the intestinal epithelia normal function of Mbd2 is required to permit tumourigenesis is supported by clinical data; CRC sequencing data and a small study looking specifically at MBD2 status [43] indicate that loss of MBD2 is a rare event in CRC patients [44,45]. However, assigning a crucial role to a gene that requires no alteration to elicit a tumourigenic function is extremely difficult and emphasises the value of this type of pre-clinical research. Which of the Mbd2 regulated genes within the intestinal epithelia are responsible for this protection remains to be established. However, it is now clear that the broad role of Mbd2 in the immune system influences Apc deficient epithelial stem cells. Evidence is now emerging that cross talk between Th cells and MHCII-expressing ISCs regulates ISC numbers and differentiation status [46]. Recent work has demonstrated a key role for two inflammatory cytokines, Ifng and Tnf and the JAK/STAT-1 signalling pathway in the reserve ISC regenerative response to acute intestinal inflammation [47]. Thus, the role of Mbd2 in controlling the CD4 and Ifng immune response is likely to be of great interest because “tumour promoting inflammation” is now identified as an enabling characteristic in the hallmarks of cancer [48]. Further investigation of Mbd2 functions should aid understanding of the links between a type 1 acute inflammatory response (the DSS-induced colitis model; Figure 2A) and an anti-tumour response. Potentially, in the early stages, the acute Th1–Ifng inflammatory response in the Mbd2 \(-/-\) mouse is associated with tumour clearance. In humans a Th1-Ifng response is a characteristic of cancer immune surveillance [49], associated with Th1 CD4+ and CD8+ T cells which directly regulate tumour cell cytotoxicity or induce
senescence, while indirectly polarizing innate immune cells toward tumour suppression[21,50]. However, the inability of these Mbd2−/− mice to resolve the inflammation, resulting in chronically inflamed intestines, despite irritant withdrawal, suggests either an auto-immune response to a self-antigen, a neo-antigen generated by the altered transcriptional profile [51] or response to bacterial translocation as a result of impaired epithelia integrity [52]. This chronic pro-tumourigenic inflammatory environment is akin to the inflammation associated cancer that develops in Crohn’s and other colitis patients. In our mouse model the inflammation can override the Mbd2 deficient dependent anti-tumour suppression mechanism to such an extent that Apc+/−/− Mbd2−/− develop adenocarcinomas which are rarely, if ever, seen in this model without an inflammatory insult. This loss of inflammatory control is potentially due to the known role of Mbd2 in promoting T-reg cell function [10]. These cells suppress immune responses of other cells and maintain self-tolerance, experimental depletion of these cells in animal experiments leads to colitis whereas in CRC patients their accumulation is associated with progression [53]. Thus, Mbd2 function may play a significant role in the progression from a protective acute response to a chronic tumour-promoting environment.

This work highlights the role that epigenetics plays in the cells of a tumour and its environment. These changes can affect the tumour itself and the delicate balance between acute and chronic inflammation which elicits anti- or pro-tumourigenic effects. Taking into consideration that in excess of 95% of CRC cases are sporadic, arising in individuals with no identified genetic predisposition[54], demonstrates that the aetiology of CRC is multifactorial - linked to genetic mutations, diet, inflammatory processes, aging, and more recently, the gut microbiota. The study of the epigenetic mechanisms which underpin these gene-environment interactions is crucial to
understand how to prevent and control this disease. Epigenetic regulation, via DNA methylation, is commonly used by all normal cells to ensure proper regulation of gene expression and stable gene silencing and is invariably altered in tumourigenesis. Recent technological advances are now leading to the identification of new genes and loci associated with inflammatory bowel diseases and CRC, based on generating methylome maps [55,56]. However, concentrating solely on the DNA methylome within the intestinal epithelium neglects the fact that the majority of the CRC associated factors impact on the epigenome within the entire body and not just the intestinal epithelium. Ultimately, interpreting the DNA methylation changes will require a more holistic approach to explain the links between the environment and CRC. We can begin to move towards this goal by exploiting existing knowledge of how DNA methylation is interpreted. The myriad of DNA methylation differences observed at an organism level are interpreted by a relatively small number of proteins [4]. Given the small number of proteins capable of interpreting the DNA methylation signal it stands to reason that some will play a major role in the multiple changes that occur to permit tumour initiation and progression. In this study, we demonstrate how loss of a single gene involved in the interpretation of DNA methylation, has pleiotropic effects on inflammation and cancer that could be environmentally regulated. In the context of understanding the relationship between the multiple factors associated with CRC this emphasises that non-cell intrinsic epigenetic changes beyond the target tissue should be considered in the attempt to unravel mechanisms.

ACKNOWLEDGMENTS
Lee Parry would like to dedicate this paper to Prof. Alan Clarke (1963-2015) who provided inspiration, mentorship, support and friendship. This work was supported by a Cancer Research UK programme grant. Lee Parry is supported by a fellowship from the European Cancer Stem Cell Research Fund. Stephanie May is supported by a philanthropic donation from the Mr Lyndon and Mrs Shirley Ann Wood from the Moorhouse Group Ltd. The authors recognise the assistance of lab technicians Sarah Davies, Elaine Tayler, Matt Zverev, Mark Bishop and Jolene Twomey.

**Author contributions statement**

LP designed research. LP, SM, TP, KG, AB (Cardiff), CT, NB-L, GRJ, PCC, ASM and GW performed research. HO and AG provided reagents and critical analysis of manuscript. LP, MS, TP, AB, ARC and OS analysed data and provided critically analysis of manuscript. LP drafted manuscript.
REFERENCES

1. Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases. *Epigenomics* 2015; 7: 247-265.
2. Bestor T, Laudano A, Mattaliano R, et al. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. *J Mol Biol* 1988; 203: 971-983.
3. Robertson KD. DNA methylation and human disease. *Nat Rev Genet* 2005; 6: 597-610.
4. Parry L, Clarke AR. The Roles of the Methyl-CpG Binding Proteins in Cancer. *Genes Cancer* 2011; 2: 618-630.
5. Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. *Cell* 1991; 65: 395-407.
6. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. *Trends Biochem Sci* 2006; 31: 89-97.
7. Menafra R, Stunnenberg HG. MBD2 and MBD3: elusive functions and mechanisms. *Front Genet* 2014; 5: 428.
8. Hutchins AS, Artis D, Hendrich BD, et al. Cutting edge: a critical role for gene silencing in preventing excessive type 1 immunity. *J Immunol* 2005; 175: 5606-5610.
9. Hutchins AS, Mullen AC, Lee HW, et al. Gene silencing quantitatively controls the function of a developmental trans-activator. *Mol Cell* 2002; 10: 81-91.
10. Wang L, Liu Y, Han R, et al. Mbd2 promotes foxp3 demethylation and T-regulatory-cell function. *Mol Cell Biol* 2013; 33: 4106-4115.
11. Kersh EN. Impaired memory CD8 T cell development in the absence of methyl-CpG-binding domain protein 2. *J Immunol* 2006; 177: 3821-3826.
12. Zhong J, Yu Q, Yang P, et al. MBD2 regulates TH17 differentiation and experimental autoimmune encephalomyelitis by controlling the homeostasis of T-bet/Hlx axis. *J Autoimmun* 2014; 53: 95-104.
13. Cook PC, Owen H, Deaton AM, et al. A dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by dendritic cells. *Nat Commun* 2015; 6: 6920.
14. Cole A, Ridgway R, Derkits S, et al. p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. *Embo Mol Med* 2010; 2: 472-486.
15. Phesse T, Parry L, Reed K, et al. Deficiency of Mbd2 attenuates Wnt signaling. *Mol Cell Biol* 2008; 28: 6094-6103.
16. Sansom OJ, Berger J, Bishop SM, et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. *Nat Genet* 2003; 34: 145-147.
17. Cui G, Goll R, Olsen T, et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. *Cancer Immunol Immunother* 2007; 56: 985-995.
18. Wang L, Wang Y, Song Z, et al. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. *J Interferon Cytokine Res* 2015; 35: 273-280.
19. Matsushita K, Takenouchi T, Shimada H, et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. *Cancer Sci* 2006; 97: 57-63.
23. Ramana CV, Grammatikakis N, Chernov M, et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000; 19: 263-272.
24. Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 2006; 146: 330-338.
25. Camoglio L, Te Velde AA, Tigges AJ, et al. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 285-290.
26. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res 2011; 17: 6118-6124.
27. Ireland H, Kemp R, Houghton C, et al. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 2004; 126: 1236-1246.
28. Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739-1742.
29. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
30. el Marjou F, Janssen K, Chang B, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004; 39: 186-193.
31. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
32. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
33. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
34. Yuan J, Reed A, Chen F, et al. Statistical analysis of real-time PCR data. BMC Bioinformatics 2006; 7: 85.
35. Platt AM, Bain CC, Bordon Y, et al. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J Immunol 2010; 184: 6843-6854.
36. Bain CC, Bravo-Blas A, Scott CL, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol 2014; 15: 929-937.
37. Webb LM, Lundie RJ, Borger JG, et al. Type I interferon is required for T helper (Th) 2 induction by dendritic cells. EMBO J 2017; 36: 2404-2418.
38. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-1390.
39. Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 2006; 146: 330-338.
40. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109.
41. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95: 7556-7561.
42. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608-611.
43. Bader S, Walker M, McQueen HA, et al. MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 2003; 22: 3506-3510.
44. Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep 2016; 15: 857-865.
45. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488: 660-664.
46. Biton M, Haber A, Beyaz S, et al. T helper cells modulate intestinal stem cell renewal and
differentiation. Biorxiv, 2017; doi.org/10.1101/217133

47. Richmond CA, Rickner H, Shah MS, et al. JAK/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation. Stem Cell Rep 2018; 10: 17-26.

48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.

49. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1-14.

50. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.

51. Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125: 3413-3421.

52. Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-258.

53. Betts G, Jones E, Junaid S, et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61: 1163-1171.

54. Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis 2011; 29: 222-228.

55. Harris RA, Nagy-Szakal D, Pedersen N, et al. Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 2334-2341.

56. Häslar R, Feng Z, Bäckdahl L, et al. A functional methylome map of ulcerative colitis. Genome Res 2012; 22: 2130-2137.
LEGENDS

Figure 1

Epithelial loss of Mbd2 in the intestine attenuates the phenotype associated with Ah-creApC deletion. (A) RT-qPCR gene expression data indicating Mbd2 loss suppresses expression of Wnt target genes following Apc deletion (N=4-6). (B) Quantification of crypt size (left panel) indicating reduction in the size of the proliferative zone and representative images of proliferative zone and Paneth cells (brown; right panel). (C) Cumulative frequency curve of Paneth cell localisation within intestinal crypt, indicating partial rescue of positioning in the Ah-creApC^{flx/flx}Mbd2^{ex1/ex1} intestine compared to Ah-creApC^{flx/flx}
Figure 2

*Mbd2* deficiency within the intestinal epithelia protects against Wnt driven tumourigenesis. (A) Kaplan-Meier survival curve indicating enhanced survival following epithelial loss of *Ah-creApc<sup>flx/flx</sup> Mbd2<sup>ex1/lox1</sup>* (N=23, p=0.005; Log-rank (Mantel-Cox) Test) compared to *Ah-creApc<sup>flx/flx</sup>* (N=20). (B) RT-qPCR expression analysis for *Mbd2* expression 180 dpi after *Ah-cre* induction indicates significant
down regulation in $Ah$-cre$Apc^{flx/flx}Mbd2^{ex1/ex1}$ mice (N=4-6). (C) Analysis of tumour number (left panel) and burden (mm$^2$; right panel) in surviving mice at 180 dpi indicates a significant decrease in the $AhcreApc^{flx/flx}Mbd2^{ex1/ex1}$ cohort.
Figure 3
Mbd2 deficiency increases susceptibility to chronic intestinal inflammation. (A) Flow cytometry plots illustrating an increase in CD4+Ifng+ cells following PMA stimulation in Mbd2−/− mice in comparison to WT. (B) Bar charts quantifying cytokine expression profiles of CD4 and CD8 lamina propria lymphocytes as a percentage of the parent population in WT and Mbd2−/− mice before and after DSS exposure. (C) Bar chart illustrating the DAI score 6 days after addition of 2% DSS to drinking water. (D) WT (left panel) and Mbd2−/− (right panel) large intestine sections illustrating crypt loss and an increase in CD4+ cell number (brown) following DSS exposure.
**Figure 4**

*Mbd2*<sup>−/−</sup> driven inflammation drives tumourigenesis in the large intestine. (A) Scoring for presence of intestinal disease, following DSS withdrawal, indicating percentage of mice with a histologically normal large intestine at different time points following exposure. (B) Representative image of *Mbd2*<sup>−/−</sup> intestine 30 days post inflammation displaying a chronic mucosal colitis with superficial ulceration (↓) and mononuclear...
infiltrate(→). (C) *Mbd2−/−* intestine 170 days post inflammation displaying an adenocarcinoma stained for mucin (blue). (D) *Mbd2−/−* mucinous adenocarcinoma displaying heterogeneous nuclear β-catenin (brown→; inset panel).

**Figure 5**

Inflammation overcomes the tumour resistance in the *Apc+/minMbd2−/−* intestine. (A) Representative image of *Apc+/minMbd2−/−* intestine 30 days post inflammation
displaying a chronic mucosal colitis with large abscess (↓) and mononuclear infiltrate (→). (B) Apc<sup>+/min</sup>Mbd2<sup>−/−</sup> intestine 180 days post onset of inflammation displaying a flat mucinous adenocarcinoma (left panel) with heterogeneous nuclear β-catenin (→; right panel). (C) Adenoma from an Apc<sup>+/min</sup> large intestine 180 days post inflammation displaying mucin filled pockets (→) and extensive nuclear β-catenin (brown).
Figure 6

*Mbd2* promotes survival of *Apc* deficient stem cells. (A) Scoring of nuclear β-catenin positive lesions indicates that at 60 days there is a reduction in *Apc*\(^{+/min}\) driven lesions due to *Mbd2* deficiency which is partially dependent on *Ifng* (*Apc*\(^{+/min}\) *N*=6, *Apc*\(^{+/min}\) *Mbd2*\(^{-/-}\) *N*=6 and *Apc*\(^{+/min}\) *Mbd2*\(^{-/-}\) *Ifng*\(^{-/-}\) *N*=6). (B) Following deletion of *Apc* in the ISC, using the *Lgr5creERT2*\(^{T2}\) *Apc\(^{flx/flx}\) (N=5) model, the number of β-catenin nuclear positive crypts in the small (left panel) and large (right panel) intestine is significantly reduced in *Lgr5creERT2*\(^{T2}\) *Apc\(^{flx/flx}\) *Mbd2\(^{flx/flx}\) mice and further reduced in the *Lgr5creERT2*\(^{T2}\) *Apc\(^{flx/flx}\) *Mbd2\(^{-/-}\) *N*=4 setting. (C) Representative image of nuclear B-catenin positive crypts (brown) in the small intestine 15 days after *Lgr5creERT2*\(^{T2}\) *Apc\(^{flx/flx}\) driven *Apc* deletion in ISC and (D) in combination with *Mbd2\(^{ex1/ex1}\) deletion.
SUPPLEMENTARY MATERIAL ONLINE

Supplementary materials and methods NO

Supplementary figure legends YES

Figure S1. Expression analysis of intestine 4 d after epithelial Mbd2 deletion indicates cell homeostasis is maintained

Figure S2. Deficiency of Mbd2 increases Ifng levels and enhances DSS-induced colitis

Figure S3. Intestinal DSS response is unaltered following vil-CreER\textsuperscript{T2} driven epithelial loss of Mbd2

Figure S4. Following an acute inflammatory insult, the Mbd2-deficient intestine develops chronic mucosal colitis (6 d post DSS administration)

Figure S5. Mbd2 promotes survival of Apc-deficient stem cells

Figure S5. MB\textsuperscript{D}2 expression is constant irrespective of intestinal tumour stage